Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 9/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 4/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568046 | 1.00 | CA2 (0.41) | CA2HRH3HTR1ASIGMAR1ADRA2A | |
| SCHEMBL30513665 | 1.00 | CA2 (0.41) | CA2HRH3HTR1ASIGMAR1ADRA2A | |
| SCHEMBL1568271 | 0.81 | CA2 (0.41) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL29398221 | 0.81 | CA2 (0.48) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL781788 | 0.81 | CA2 (0.48) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL15219655 | 0.81 | CA2 (0.48) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL29386661 | 0.81 | CA2 (0.48) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4830484 | 0.81 | CA2 (0.48) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL12060988 | 0.81 | HRH3 (0.49) | HRH3NISCH | |
| SCHEMBL30142986 | 0.81 | HRH3 (0.49) | HRH3NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038067-B2 | Process for synthesizing d-tocotrienols from 2-vinylchromane compound | YASOO HEALTH, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-7038067-B2 | Process for synthesizing d-tocotrienols from 2-vinylchromane compound | YASOO HEALTH, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050124688-A1 | Process for synthesizing d-tocotrienols from 2-vinylchromane compound | YASOO HEALTH, INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050124688-A1 | Process for synthesizing d-tocotrienols from 2-vinylchromane compound | YASOO HEALTH, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005035491-A3 | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND | YASOO HEALTH INC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005035491-A2 | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND | YASOO HEALTH, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005035491-A2 | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND | YASOO HEALTH, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124688-A1 | Process for synthesizing d-tocotrienols from 2-vinylchromane compound | FDFT1, DHCR7, DDT | CA2 4376/4885HRH3 728/4885HTR1A 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.